Pretomanid

Names: PA-824
Chemical class: Nitroimidazole
Background

Pretomanid is a nitroimidazole, a class of novel anti-bacterial agents. As a potential TB therapy, it has many attractive characteristics - most notably its novel mechanism of action, its activity in vitro against all tested drug-resistant clinical isolates, and its activity as both a potent bactericidal and a sterilizing agent in mice. In addition, the compound shows no evidence of mutagenicity in a standard battery of genotoxicity studies, no significant cytochrome P450 interactions, and no significant activity against a broad range of Gram-positive and Gram-negative bacteria. This compound has been developed by TB Alliance and is a potential cornerstone of future TB and drug-resistant TB treatment regimens.

Additional resources:

Peer-reviewed publications

 

Clinical Trials

 

Phase 2 (Advanced)

Regimen Associations

This compound has appeared in the following regimens:

Trial Associations

This compound has appeared in the following trials: